M
Michael A. Danso
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 52
Citations - 3948
Michael A. Danso is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 18, co-authored 40 publications receiving 3224 citations. Previous affiliations of Michael A. Danso include University of Kansas & Texas Oncology.
Papers
More filters
Journal ArticleDOI
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Paul J. Hesketh,Mark G. Kris,Ethan Basch,Kari Bohlke,Sally Y. Barbour,Rebecca Clark-Snow,Michael A. Danso,Kristopher Dennis,L. Lee Dupuis,Stacie B. Dusetzina,Cathy Eng,Petra Feyer,Karin Jordan,Kimberly Noonan,Dee Sparacio,Mark R. Somerfield,Gary H. Lyman +16 more
TL;DR: The Update Committee noted the importance of continued symptom monitoring throughout therapy, and Clinicians underestimate the incidence of nausea, which is not as well controlled as emesis.
Journal ArticleDOI
Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer
Ayca Gucalp,Ayca Gucalp,Sara M. Tolaney,Steven J. Isakoff,James N. Ingle,Minetta C. Liu,Lisa A. Carey,Kimberly L. Blackwell,Hope S. Rugo,Lisle Nabell,Andres Forero,Vered Stearns,Ashley S. Doane,Michael A. Danso,Mary Ellen Moynahan,Lamia Momen,Joseph Gonzalez,Arooj Akhtar,Dilip Giri,Sujata Patil,Kimberly Feigin,Clifford A. Hudis,Clifford A. Hudis,Tiffany A. Traina,Tiffany A. Traina +24 more
TL;DR: The CBR of 19% observed with bicalutamide shows proof of principle for the efficacy of minimally toxic androgen blockade in a select group of patients with ER/PgR-negative, AR-positive breast cancer.
Journal ArticleDOI
An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen
Ashley S. Doane,Michael A. Danso,Priti Lal,M. Donaton,Liying Zhang,Clifford A. Hudis,William L. Gerald +6 more
TL;DR: This subset of BCs, characterized by a hormonally regulated transcriptional program and response to androgen, suggests the potential for therapeutic strategies targeting the androgen signaling pathway.
Journal ArticleDOI
Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
Joyce O'Shaughnessy,Lee S. Schwartzberg,Michael A. Danso,Kathy D. Miller,Hope S. Rugo,Marcus Neubauer,Nicholas J. Robert,Beth A. Hellerstedt,Mansoor N. Saleh,Paul Richards,Jennifer M. Specht,D. A. Yardley,Robert W. Carlson,Richard S. Finn,Eric Charpentier,Ignacio Garcia-Ribas,Eric P. Winer +16 more
TL;DR: The trial did not meet the prespecified criteria for the coprimary end points of PFS and OS in the ITT population, and the potential benefit with iniparib observed in second-/third-line subgroup warrants further evaluation.
Journal ArticleDOI
A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).
Joyce A. O'Shaughnessy,Lee S. Schwartzberg,Michael A. Danso,Hope S. Rugo,Kathy D. Miller,D. A. Yardley,Robert W. Carlson,R. S. Finn,Eric Charpentier,M. Freese,S. Gupta,A. Blackwood-Chirchir,EP Winer +12 more
TL;DR: This confirmatory study evaluated the safety and efficacy of GC with or without I in a similar mTNBC pt population and found that addition of I did not significantly add to the toxicity profile of GC alone.